drugset
Drugs / ALVAC(2)120(B,MN)GNP
last change Jun 2007 re-read 9 days ago

ALVAC(2)120(B,MN)GNP

also known as vCP1452 · ALVAC-HIV

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · New York Presbyterian Hospital

Trials 10

today NCT00006509 · Ph 1 NCT00026624 · Ph 1 NCT00013663 · Ph 2 NCT00027261 · Ph 1 NCT00006291 · Ph 2 NCT00005758 · Ph 3 NCT00000879 · Ph 1 NCT00011037 · Ph 2 NCT00007332 · Ph 2 NCT00011011 · Ph 1/2
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials · 2 missed
Phase 1 NCT00000879 ? → Apr 2005 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00026624 ? → Oct 2006 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed Missed primary
Phase 1 NCT00006509 ? → Jun 2007 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00027261 ? → Dec 2005 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed Missed primary
Phase 1/21 trial
Phase 1/2 NCT00011011 Feb 2001 → Oct 2006 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 24 trials
Phase 2 NCT00013663 ? → Jun 2006 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT00006291 ? → Oct 2005 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT00011037 ? → Jul 2004 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT00007332 ? → Apr 2003 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 31 trial
Phase 3 NCT00005758 ? → Sep 2005 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as ALVAC(2)120(B,MN)GNP ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006291 ↗
9

NCT00007332 ↗

NCT00000879 ↗

NCT00005758 ↗

NCT00026624 ↗

NCT00027261 ↗

NCT00011037 ↗

NCT00013663 ↗

NCT00006509 ↗

NCT00011011 ↗
Known as ALVAC-HIV “The purpose of this study is to test how the body's immune system responds to the vaccine ALVAC-HIV vCP1452 and to determine if the vaccine is safe when given alone and with MN rgp120.” NCT00011037 ↗
2

“Group B: Patients receive an SC vaccination with ALVAC-HIV vCP1452 without DCs.” NCT00026624 ↗

“HIV vaccine (ALVAC-HIV vCP1452)” NCT00006291 ↗
Known as vCP1452 “canarypox HIV-vaccine (vCP1452)” NCT00013663 ↗
8

“HIV vaccine (ALVAC-HIV vCP1452)” NCT00006291 ↗

“ALVAC(2)120(B,MN)GNP (vCP1452)” NCT00011037 ↗

“ALVAC(2)120(B,MN)GNP (vCP1452)” NCT00011011 ↗

“ALVAC(2)120(B,MN)GNP (vCP1452)” NCT00026624 ↗

“ALVAC(2)120(B,MN)GNP (vCP1452)” NCT00007332 ↗

“ALVAC(2)120(B,MN)GNP (vCP1452)” NCT00000879 ↗

“ALVAC(2)120(B,MN)GNP (vCP1452)” NCT00005758 ↗

“ALVAC(2)120(B,MN)GNP (vCP1452)” NCT00006509 ↗
Modality Vaccine “The purpose of this study is to see if giving the ALVAC vCP1452 anti-HIV vaccine alone or with another vaccine called AIDSVAX B/B to babies of HIV-positive mothers is safe.” NCT00000879 ↗
Route Other “Patients receive vaccine (or vaccine placebo) injections” NCT00006291 ↗